Molecules · 2023 · 13 citations · 33 references
Life SciencesImmunologyMicrobiologyImmunizationMucosal ImmunologyVaccinologyBacterial SporesMucosal ImmunizationMucosal VaccinesVaccinationVaccine DeliveryVector-based VaccinesBacillus SporesBacterial Vector VaccineMucosal Immunoglobulin A (Iga) ResponsesSars-cov-2 InfectionSpore Coat StructureVaccine Delivery FormulationsVaccine ProductionVaccine Strain Development
Vaccination is the most effective method of combating COVID-19 infection, but people with a psychological fear of needles and side effects are hesitant to receive the current vaccination, and alternative delivery methods may help. Bacillus subtilis, a harmless intestinal commensal, has recently earned a strong reputation as a vaccine production host and delivery vector, with advantages such as low cost, safety for human consumption, and straightforward oral administration. In this study, we have succeeded generating “S spores” by engineering B. subtilis with spore coat proteins resembling the spike (S) protein of the ancestral SARS-CoV-2 coronavirus. With the addition of two immunostimulating natural products as adjuvants, namely Astragalus membranaceus (Fisch.) Bge (AM) and Coriolus versicolor (CV), oral administration of S spores could elicit mild immune responses against COVID-19 infection without toxicity. Mucosal IgA against the S protein was enhanced by co-feeding with AM and CV in an S spores-inoculated mouse model. Faster and stronger IgG responses against the S protein were observed when the mice were fed with S spores prior to vaccination with the commercial COVID-19 vaccine CoronaVac. In vitro studies demonstrated that AM, CV, and B. subtilis spores could dose-dependently activate both macrophages and dendritic cells by secreting innate immunity-related IL-1β, IL-6, and TNF-α, and some other proinflammatory chemokines and cytokines. In conclusion, the combination of S spores with AM and CV may be helpful in developing a vaccine-like supplement against respiratory infection.
33
Yanjun Zhang, Gang Zeng, Hongxing Pan et al. · The Lancet Infectious Diseases · 2020 · 1.5K citations · Full text
Shengli Xia, Yuntao Zhang, Yanxia Wang et al. · The Lancet Infectious Diseases · 2020 · 1.2K citations · Full text
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
Qian Wang, Sho Iketani, Zhiteng Li et al. · Cell · 2022 · 946 citations · Full text
Zhiwei Wu, Yaling Hu, Miao Xu et al. · The Lancet Infectious Diseases · 2021 · 575 citations · Full text